NMD4C Welcomes Two New Staff Members

The NMD4C recently welcomed two new members to the network coordination team! Victoria Larocca, PhD joins us as the new Training and Curriculum Coordinator, and Zainab Adamji joins as the Outcome Measures and Natural History Coordinator. 

 

Victoria Larocca, PhD | Training and Curriculum Coordinator

NMD4C Training and Curriculum Coordinator Victoria Larocca

Victoria is a dedicated knowledge mobilization specialist with a passion for advancing health research and education. She earned her Ph.D. and M.Sc. in Kinesiology and Health Science from York University in 2022 and 2018, respectively, following her Bachelor of Education from Brock University in 2016.

Throughout her academic journey, Victoria has immersed herself in health psychology and clinical research. With her experience and education in health research, Victoria is committed to advancing the education and curriculum for neuromuscular trainees as well as advancing the research conducted at Muscular Dystrophy Canada.

 

Zainab Adamji | Outcome Measures and Natural History Coordinator

Zainab Adamji

Zainab is a dedicated knowledge mobilization specialist with a passion for translating research into practical applications and influencing policy. She earned her Honours B.Sc. in Biology, specializing in Biotechnology, from the University of Waterloo in 2020, followed by an MSc in Molecular Science from Toronto Metropolitan University in 2022. During her academic studies, Zainab researched lysosome dysfunction and its intricate impacts on organelle cross-talk. Zainab has supported numerous research and advocacy initiatives at Muscular Dystrophy Canada and has further honed her expertise through the MobilizeU knowledge mobilization certification program at York University.

Within her role at the NMD4C, Zainab works to coordinate NMD outcome measures, developing training modules and provide training on validated NMD outcome measures, and selecting patient-reported outcome measures to be captured in post-market surveillance patient registries.

 

NMD4C Hires two new Coordinators - Zainab and Victoria

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.